Management of fulminating ulcerative colitis in childhood with chimeric anti-CD25 antibody

Journal of Pediatric Gastroenterology and Nutrition

Volumn 42, Issue 2, 2006, Pages 245-248

  Schwarzer, A ^a   Ricciardelli, I ^b   Kirkham, S ^b   Binnie, K ^b   Shah, N ^b   Elawad, M A ^b   Hill, S M ^b   Furman, M ^b   Smith, V V ^c   Sebire, N ^c   Milla, P J ^b   Londei, M ^b   Lindley, K J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c Camelia Botnar Laboratories   (United Kingdom)

Author keywords

Calcineurin inhibition; CD25; Colectomy; Pediatric; Ulcerative colitis

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; KETAMINE; METHYLPREDNISOLONE; STEROID; TACROLIMUS;

ADOLESCENT; ALGORITHM; ARTICLE; CASE REPORT; CHILD; COLON BIOPSY; COLON RESECTION; COLONOSCOPY; DISEASE ACTIVITY; DISEASE COURSE; HEALING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ACUTE DISEASE; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTIBODIES, ANTI-IDIOTYPIC; CALCINEURIN; CHILD; COLECTOMY; COLITIS, ULCERATIVE; HUMANS; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646093950     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000189347.32796.c5     Document Type: Article

References (16)

1. Daperno M, Sostegni R, Rocca R, et al. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2002;16(Suppl 4):7-12.
2. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
3. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5): V1-16.
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
5. Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987;9:50-4.
6. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003;15:239-44.
7. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-7.
8. Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-76.
9. Martin PJ, Pei J, Gooley T, et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 2004;10:552-60.
10. Schappi MG, Smith VV, Goldblatt D, Lindley KJ, Milla PJ. Colitis in chronic granulomatous disease. Arch Dis Child 2001;84:147-51.
11. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079-87.
12. Rowshani AT, Uss A, Yong SL, van Lier RA, ten Berge IJ. Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro. Eur J Immunol 2004;34:882-99.
13. Xiao S, Sung SS, Fu SM, Ju ST. Combining Fas mutation with interleukin-2 deficiency prevents Colitis and Lupus: implicating interleukin-2 for auto-reactive T cell expansion and Fas ligand for colon epithelial cell death. J Biol Chem 2003;278:52730-8.
14. Kircher B, Latzer K, Gastl G, Nachbaur D. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 2003;134:426-30.
15. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123-31.
16. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003;75:37-43.